Eli Lilly has marked a significant milestone by becoming the second company to receive approval for a weight-loss pill in the U.S. This development signals a shift in the multibillion-dollar weight-loss market, which is increasingly gravitating towards more accessible oral therapies.
As the global landscape for weight-loss drugs evolves, generic competitors are emerging, and prices for leading treatments from Eli Lilly and Novo Nordisk are starting to decline. These changes have led analysts to reassess their long-term predictions for a market that could reach $150 billion within the next decade.
Pioneers in Oral Obesity Treatments
Novo Nordisk was the first to introduce a GLP-1 oral pill specifically for obesity, positioning itself advantageously within the competitive obesity treatment sector. The U.S. Food and Drug Administration approved this pill in December, and other regulatory bodies are currently reviewing it, with an expected UK decision by the end of the year.
Novo’s orforglipron, branded as Foundayo, has demonstrated effectiveness in helping overweight adults without diabetes achieve a 12.4% reduction in body weight over 72 weeks, with the highest dose showing the most promise. In a separate study, orforglipron proved successful in maintaining weight loss for patients transitioning from injectable treatments like Zepbound and Wegovy.
Emerging Players and Innovations
Structure Therapeutics is making strides with its candidate GSBR-1290, a non-peptide oral GLP-1 agonist that has shown an 11.3% weight loss in a mid-stage trial involving 230 participants over 36 weeks. The company is set to advance to late-stage development by mid-2026, contingent upon discussions with the FDA in the upcoming year.
Additionally, Structure is collaborating with Hansoh Pharma to develop HS-10535, an oral small-molecule GLP-1 agonist currently in the laboratory testing phase.
AstraZeneca and Eccogene’s Progress
AstraZeneca, in conjunction with Eccogene, is progressing with ECC5004, a once-daily GLP-1 receptor agonist pill. Early trials have indicated promising weight-loss results paired with a favorable safety profile, leading to plans for mid-stage trials spearheaded by AstraZeneca.
Roche, following its acquisition of Carmot Therapeutics, is also advancing CT-966, an oral GLP-1 agonist. Preliminary studies revealed a placebo-adjusted average weight loss of 6.1% within four weeks among obese patients without diabetes.
Pfizer’s Strategic Moves
Pfizer has entered the competitive obesity drug arena through its substantial acquisition of Metsera, a developer of obesity medications, for $10 billion. This acquisition grants Pfizer access to two long-acting oral GLP-1 drugs that are currently in preclinical trials.
In partnership with Chinese firm Sciwind Biosciences, Pfizer has received approval for its once-weekly weight-loss injection, Xianweiying, in China. This development intensifies competition against established products from Novo, Lilly, and Innovent Biologics.
Despite initial enthusiasm, Pfizer discontinued the development of danuglipron, a twice-daily oral GLP-1 agonist, due to poor tolerability observed in mid-stage trial data.
Global Competitors in the Market
Innovent Biologics, based in China, is testing its oral GLP-1 weight-loss drug, IBI3032, in early-stage trials in both the U.S. and China. Similarly, HuaDong Pharmaceutical’s HDM1002, another oral obesity drug candidate from China, demonstrated a weight reduction of up to 6.8% in an early-stage study.
Ascletis Pharma, also from China, has shown promise with its experimental oral GLP-1 drug, ASC30, which reported weight loss of up to 7.7% in a mid-stage study in the U.S.
Market Dynamics and Future Outlook
The burgeoning interest in oral weight-loss therapies is reshaping the pharmaceutical landscape. As more companies enter the fray with innovative solutions, the competitive dynamics will likely drive advancements in treatment efficacy and safety.
The increasing prevalence of obesity-related health issues underlines the urgency for effective weight-loss solutions. The ongoing race among pharmaceutical companies to develop and launch oral therapies reflects a broader commitment to addressing this global health challenge.
Key Takeaways
- Eli Lilly’s approval for a weight-loss pill signifies a transformative moment in the obesity treatment market.
- Novo Nordisk maintains a competitive edge with its first-mover advantage in GLP-1 oral therapies.
-
Structure Therapeutics and AstraZeneca are among the emerging players making significant progress in oral GLP-1 drug development.
-
Pfizer’s strategic acquisition enhances its position in the obesity drug market but highlights the challenges of drug tolerability.
-
International competitors from China are actively contributing to the innovation landscape in weight-loss therapies.
In conclusion, the race to develop effective oral weight-loss medications is intensifying, with key players making significant strides. As innovations continue to emerge, the market may reshape how obesity is treated in the coming years, offering new hope to those in need of effective solutions.
Read more → www.aol.com